Eli Lilly drops CVS drug plan for workers after Novo obesity deal, Bloomberg News reports

Core Point - Eli Lilly is terminating its partnership with CVS Health's drug benefit plan for employees due to CVS's decision to stop covering Eli Lilly's weight-loss drug in favor of a competing product from Novo Nordisk [1] Company Impact - The decision by Eli Lilly reflects a strategic response to CVS Health's shift in drug coverage, which may impact Eli Lilly's market position and sales of its weight-loss medication [1] Industry Context - The move highlights the competitive landscape in the pharmaceutical industry, particularly in the weight-loss drug segment, where companies like Novo Nordisk are gaining traction [1]